RecruitingEarly Phase 1NCT07250854

The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis


Sponsor

University of Alabama at Birmingham

Enrollment

15 participants

Start Date

Jan 23, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

In infants that present with findings concerning for biliary atresia, along with other cholestatic work up which is standard, they will receive a one-time intravenous (IV) dose of Indocyanine Green (ICG). The infant's diapers will subsequently be examined for presence of the ICG, and if present, suggests bile flow. This was described as 97% accurate for assessing biliary patency and we would like to perform a similar study to assess biliary patency in the work up of neonatal cholestasis.


Eligibility

Min Age: 2 WeeksMax Age: 4 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Indocyanine Green for people with biliary atresia, cholestasis in newborn, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Weeks to 4 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIndocyanine Green

Optical imaging agent


Locations(1)

University of Alabama At Birmingham

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07250854


Related Trials